MakroCare Partners with LSK Global in Asian Expansion

US-headquartered trial services firm MakroCare has continued its expansion in Asia with a new partnership with South Korea-based CRO LSK Global, according to Outsourcing-Pharma.

The deal, financial terms of which have not been disclosed, will see the firms provide client and promotional support for drug development, trial management and commercialization services in their respective territories.

MakroCare president Mahesh Malneedi told Outsourcing-Pharma that a key motivation for the collaboration was supporting the firm's activities in Asia, particularly in the world's second biggest pharmaceutical market Japan where it has operated for the past two years.

"For Asian trials that need to be submitted to Japan, where PMDA accepts data mostly from Japan, Korea, Taiwan and China, we need other countries data to support our Japanese operations," said Malneedi.

Beyond Japan Malneedi said teaming with LSK gives access to Korea and Taiwan which he called "very good markets for high-end products in pharma, biotech and devices where we are seeing more interest in doing trials by multi-nationals as part of product extension strategy."

MakroCare, an international Drug Development and Commercialization services firm, and LSK Global, a Korean CRO headquartered in Seoul, recently announced the signing of an alliance agreement.

One Washington Park
Suite 1303
Newark, NJ 07102
Phone: (973) 481 0100
Fax: (973) 481 1020

This release was published on openPR.